Advanced Renal Cell Carcinoma: Selecting Between IO/TKI and IO/IO Combination Therapy

Dr. Monty Pal reviews how current clinical guidelines support both immunotherapy plus tyrosine kinase inhibitor (IO/TKI) combinations and dual immunotherapy (IO/IO) as frontline treatment options for advanced renal cell carcinoma (RCC). He discusses the patient- and disease-specific factors that influence his treatment selection, emphasizing that no single clinical characteristic definitively determines the optimal approach. Dr. Pal explains that patients with favorable-risk disease warrant a thoughtful discussion of both treatment strategies, while those with symptomatic, rapidly progressive disease or a high disease burden, such as bone metastases, may be more appropriate candidates for an IO/TKI combination because of the need for prompt disease control. He also highlights the limitations of current predictive tools, noting that carefully selected patients treated with dual immunotherapy can achieve durable clinical benefit. The discussion reinforces the importance of individualized treatment selection based on disease biology, clinical presentation, and patient preferences in advanced renal cell carcinoma.